US2007154491A1PendingUtilityA1
Edible vaccine
Est. expirySep 10, 2024(expired)· nominal 20-yr term from priority
A61K 36/06A61K 2039/543A61K 2039/542A61K 2039/523A61K 9/19C12N 2710/20034A61P 31/00A61P 35/00A61K 2039/5258A61P 31/12A61K 2039/55544A61K 39/12A61K 39/23
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The object of the present invention is to provide an edible vaccine which is effective for human papilloma virus (HPV) type 16 and available in large amounts inexpensively. An edible human papilloma virus vaccine obtained by culturing a transformant of an avirulent fission yeast host, wherein the transformant carries a gene encoding an antigenic protein of human papilloma virus introduced therein and accumulates the expressed antigenic protein in it.
Claims
exact text as granted — not AI-modified1 . An edible human papilloma virus vaccine obtained by culturing a transformant of an avirulent fission yeast host, wherein the transformant carries a gene encoding an antigenic protein of human papilloma virus introduced therein and accumulates the expressed antigenic protein in it.
2 . The vaccine according to claim 1 , wherein the avirulent fission yeast host is Schizosaccharomyces pombe.
3 . The vaccine according to claim 1 , wherein the human papilloma virus is human papilloma virus type 16 (HPV16).
4 . The vaccine according to claim 1 , wherein the gene encoding an antigenic protein is a gene encoding a capsid protein of the human papilloma virus.
5 . The vaccine according to claim 4 , wherein the capsid protein of the human papilloma virus is the L1 protein.
6 . The vaccine according to claim 4 , wherein the capsid protein of the human papilloma virus is the L1 protein of human papilloma protein type 16 (HPV16-L 1 ).
7 . The vaccine according to claim 4 , wherein the protein accumulated in the transformant is assembled into virus-liked particles.
8 . The vaccine according to claim 1 , wherein the vaccine is a freeze-dried preparation of the transformant.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.